ID: ALA601003

Max Phase: Preclinical

Molecular Formula: C24H21Cl2N3O5

Molecular Weight: 502.35

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C(Oc1ccc([N+](=O)[O-])cc1)N1CCN(Cc2cccc(Oc3cc(Cl)cc(Cl)c3)c2)CC1

Standard InChI:  InChI=1S/C24H21Cl2N3O5/c25-18-13-19(26)15-23(14-18)33-22-3-1-2-17(12-22)16-27-8-10-28(11-9-27)24(30)34-21-6-4-20(5-7-21)29(31)32/h1-7,12-15H,8-11,16H2

Standard InChI Key:  SKBPJYZOLUWFRB-UHFFFAOYSA-N

Associated Targets(non-human)

Anandamide amidohydrolase 476 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Monoglyceride lipase 234 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Monoacylglycerol lipase ABHD6 221 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Neuropathy target esterase 29 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 502.35Molecular Weight (Monoisotopic): 501.0858AlogP: 6.01#Rotatable Bonds: 6
Polar Surface Area: 85.15Molecular Species: NEUTRALHBA: 6HBD: 0
#RO5 Violations: 2HBA (Lipinski): 8HBD (Lipinski): 0#RO5 Violations (Lipinski): 2
CX Acidic pKa: CX Basic pKa: 6.25CX LogP: 5.91CX LogD: 5.88
Aromatic Rings: 3Heavy Atoms: 34QED Weighted: 0.30Np Likeness Score: -1.48

References

1. Long JZ, Jin X, Adibekian A, Li W, Cravatt BF..  (2010)  Characterization of tunable piperidine and piperazine carbamates as inhibitors of endocannabinoid hydrolases.,  53  (4): [PMID:20099888] [10.1021/jm9016976]

Source